Fmoc-PEG4-Glu-Gly-Cit-PAB-MMAE is an antibody drug conjugate (ADC) precursor, including a cathepsin-cleavable Glu-Gly-Cit (EGCit) tripeptide, PABC linker, and MMAE payload. It can be attached to a monoclonal antibody (mAb) which directs it toward cancer cells. This peptide exhibits remarkable stability in the bloodstream. Also, it resists degradation and human neutrophil protease cleavage, while still enabling the intracellular release of payloads in a discrete, traceless manner.
Usually ships within 24 hours.